Palmar plantar erythrodysesthesia epidemiology and demographics
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics |
|
FDA on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
CDC on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
Palmar plantar erythrodysesthesia epidemiology and demographics in the news |
|
Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Zain Fatiwala, M.D.
Overview
PPE occurs in 6-42% of patients receiving chemotherapy.[1] In BMT patients, there is a 35% incidence of PPE and may be due to the use of high doses of chemotherapy with addition of total body irradiation.[2]
Epidemiology and demographics
PPE occurs in 6-42% of patients receiving chemotherapy.[1]
Several authors have reported that the incidence of PLD-associated hand and foot syndrome for patients with any grade of PPE is about 50% and for patients with grade 3 and grade 4 PPE the incidence is about 20% for a PLD dose of 50 mg/m2 every 4 weeks [3], [4]. According to evidence, it has been determined that a dose of 40 mg/m2 every 4 weeks is at present considered equally effective and less toxic. This has become a preferred dosage[5].
In BMT patients, there is a 35% incidence of PPE and may be due to the use of high doses of chemotherapy with addition of total body irradiation.[6]
References
- ↑ 1.0 1.1 Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Crider MK, Jansen J, Norins AL, McHale MS (1986). "Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation". Arch Dermatol. 122 (9): 1023–7. PMID 3527075.
- ↑ O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A; et al. (2004). "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer". Ann Oncol. 15 (3): 440–9. PMID 14998846.
- ↑ Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001). "Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan". J Clin Oncol. 19 (14): 3312–22. doi:10.1200/JCO.2001.19.14.3312. PMID 11454878.
- ↑ Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007). "Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)". Ann Oncol. 18 (7): 1159–64. doi:10.1093/annonc/mdl477. PMID 17229768.
- ↑ Crider MK, Jansen J, Norins AL, McHale MS (1986). "Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation". Arch Dermatol. 122 (9): 1023–7. PMID 3527075.